Ligand Partner Eisai Receives Approval In Japan For Injection Formulation Of Antiepileptic Drug Fycompa
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its partner Eisai Co., Ltd. received approval in Japan for an injection formulation of the antiepileptic drug Fycompa, formulated with Ligand's Captisol technology. This marks the 16th Captisol-enabled product approved worldwide. Ligand is entitled to royalties from sales of this new formulation. Fycompa, a first-in-class AED, targets glutamate activity at AMPA receptors to reduce seizures. It is approved in over 75 countries for various forms of epilepsy.
February 22, 2024 | 9:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ligand Pharmaceuticals' Captisol technology enables the new injection formulation of Fycompa by Eisai, approved in Japan. Ligand to receive royalties, marking a positive development.
The approval of the Fycompa injection formulation in Japan, utilizing Ligand's Captisol technology, represents a significant milestone for Ligand Pharmaceuticals. This development not only expands the global footprint of Captisol-enabled products but also ensures a new revenue stream for Ligand through royalties from sales. Given the drug's approval in a major market like Japan and its potential impact on patient care, this news is likely to be viewed positively by investors, potentially leading to a short-term uptick in Ligand's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100